
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **Collagens (COL1A1, COL1A2, COL3A1, COL11A1, COL5A1, COL5A2, COL12A1, COL6A3, COL6A2, COL6A1, COL10A1, COL8A1):** These are structural proteins that form the extracellular matrix (ECM) and provide structural support to tissues.<br>- **Matrix Metalloproteinases (MMP11, MMP2, MMP14):** Enzymes that degrade various components of the ECM, involved in tissue remodeling and cancer metastasis.<br>- **Integrins (ITGA11):** Receptors that mediate cell-ECM adhesion, playing roles in cell signaling and migration.<br>- **Fibronectin (FN1):** A glycoprotein involved in cell adhesion and migration processes.<br>- **Periostin (POSTN):** A matricellular protein involved in tissue repair and remodeling.<br>- **Thrombospondin (THBS2):** Involved in cell-to-cell and cell-to-matrix communication.<br>- **Decorin (DCN), Lumican (LUM), Biglycan (BGN):** Small leucine-rich proteoglycans involved in collagen fibrillogenesis and ECM organization.<br>- **Fibulin (FBLN2):** Involved in the stabilization of ECM structures.<br>- **Versican (VCAN):** A large chondroitin sulfate proteoglycan involved in cell adhesion, proliferation, and migration.<br>- **Cathepsin K (CTSK):** A protease involved in bone resorption and ECM degradation.<br>- **Insulin-like Growth Factor Binding Protein 7 (IGFBP7):** Modulates IGF signaling and is involved in cell adhesion and migration.<br><br>### Step 2: List the Key Cell Type Markers<br>- **PDGFRB (Platelet-Derived Growth Factor Receptor Beta):** A marker for pericytes and fibroblasts, involved in cell proliferation and migration.<br>- **THY1 (CD90):** A marker for fibroblasts and mesenchymal stem cells.<br>- **SPARC (Secreted Protein Acidic and Rich in Cysteine):** A marker for fibroblasts, involved in ECM production and remodeling.<br>- **AEBP1 (Adipocyte Enhancer-Binding Protein 1):** Associated with fibroblasts and involved in ECM organization.<br>- **ADAMTS2 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 2):** Involved in collagen processing, associated with fibroblasts.<br>- **RARRES2 (Retinoic Acid Receptor Responder 2):** Associated with fibroblasts and involved in immune response modulation.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and PanglaoDB, these markers are predominantly associated with fibroblasts, particularly cancer-associated fibroblasts (CAFs) in the context of breast cancer.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of these markers, the most likely general cell type is **fibroblasts**. The presence of ECM components, matrix remodeling enzymes, and fibroblast-specific markers strongly suggests this cell type.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Cancer-Associated Fibroblasts (CAFs):** Given the context of breast cancer tissue, the expression of ECM components, remodeling enzymes, and fibroblast markers strongly indicates CAFs, which play a role in tumor progression and metastasis.<br>2. **Myofibroblasts:** Characterized by the expression of ECM components and contractile proteins, myofibroblasts are involved in wound healing and fibrosis.<br>3. **Pericytes:** Although less likely, the presence of PDGFRB suggests a potential overlap with pericyte markers, which are involved in vascular stability and angiogenesis.<br><br>The most likely subtype based on the markers is **Cancer-Associated Fibroblasts (CAFs)**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The ranked marker list from the breast cancer tissue dataset predominantly features genes associated with ECM production, remodeling, and fibroblast-specific markers. Cross-referencing with known databases and literature, the most probable general cell type is fibroblasts, with the top subtype being Cancer-Associated Fibroblasts (CAFs). These cells are crucial in the tumor microenvironment, contributing to cancer progression and metastasis.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency:**<br>   - The markers listed in the annotation result are present in the provided marker list. <br>   - The markers are consistent with the identification of fibroblasts, particularly Cancer-Associated Fibroblasts (CAFs), as they include ECM components (e.g., collagens, fibronectin), matrix remodeling enzymes (e.g., MMPs), and fibroblast-specific markers (e.g., PDGFRB, THY1, SPARC).<br><br>2. **Mixed Cell Type Consideration:**<br>   - The annotation acknowledges the potential presence of myofibroblasts and pericytes, which is appropriate given the expression of markers like PDGFRB that can overlap with pericyte markers.<br>   - However, the strong presence of fibroblast and ECM-related markers supports the primary identification of CAFs, which is reasonable given the context of breast cancer tissue.<br><br>The annotation is well-supported by the marker list and the context provided, and the potential for mixed cell types has been appropriately flagged for further consideration.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">fibroblasts</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Cancer-Associated Fibroblasts (CAFs)</li><li>Myofibroblasts</li><li>Pericytes</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the marker list and its implications for identifying cell types within the context of human breast cancer tissue. The analysis correctly identifies fibroblasts, particularly Cancer-Associated Fibroblasts (CAFs), as the primary cell type, which is consistent with the expression of numerous ECM-related markers such as collagens, fibronectin, and matrix metalloproteinases. This is scientifically accurate given the role of CAFs in the tumor microenvironment and their contribution to cancer progression and metastasis.<br><br>The annotation also considers the potential presence of myofibroblasts and pericytes, which is a balanced approach given the expression of markers like PDGFRB that can overlap with pericyte markers. This demonstrates an awareness of the complexity and heterogeneity of cell populations within the tumor microenvironment.<br><br>However, while the annotation does a good job of identifying the primary cell type and potential subtypes, it could benefit from a more detailed discussion of the rank and relative importance of the markers. For instance, while collagens and ECM components are heavily represented, the annotation could have emphasized the significance of the top-ranked markers more explicitly, as these are likely to have a greater influence on the cell type identification.<br><br>Overall, the annotation provides a comprehensive view of the cell types present, with no obvious misclassifications or oversights. The analysis is well-supported by the marker list and the context of breast cancer tissue, capturing the general picture effectively.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    